# Aadi Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aadi-bioscience

- Industry: Pharmaceuticals
- Headquarters: Los Angeles, US
- Website: www.aadibio.com
- Total disclosed funding: $23M
- Latest round: Series A (May 8, 2017)
- Investors on record: 6

## About

Aadi Bioscience, Inc. is a US-based biotechnology firm focused on developing precision medicine solutions for mTOR-driven diseases, utilizing advanced nanoparticle technology for improved treatment efficacy.Aadi Bioscience, Inc. specializes in precision medicine and was founded in 2007 in Los Angeles, US. Under the leadership of CEO Dave Lennon, the company has executed 4 deals, with its most recent funding round occurring on December 19, 2024. The company raised USD 100 mn in PIPE funding, which was led by Ally Bridge Group, with participation from several other investors. The total amount raised to date is USD 100 mn. Aadi does not have a parent company or subsidiaries.Aadi Bioscience is dedicated to the development and commercialization of precision medicine solutions, particularly for mTOR-driven diseases, using albumin-bound nanoparticle technology. Its primary offerings consist of advanced therapeutics designed to overcome the limitations of traditional mTOR inhibitors, focusing on rare malignancies such as advanced malignant PEComa. By employing genomic profiling technology, Aadi is able to pinpoint patients who stand to gain the most from these targeted treatments, catering to markets in North America, Europe, and Asia-Pacific.In 2022, Aadi Bioscience generated revenue of USD 15.22 mn alongside an EBITDA of USD -63.74 mn. Revenue is primarily derived from partnerships with healthcare providers and institutions that facilitate the distribution of its precision medicine products, reflecting a transaction model that is closely tied to B2B engagements.Aadi Bioscience plans to utilize the USD 100 mn raised from its recent PIPE funding round to drive the development and launch of new therapeutic options, aiming to enhance its product offerings by targeting additional mTOR-driven diseases. The company is also looking to expand its market presence into Europe and Asia-Pacific by the end of 2025, taking advantage of the increasing demand for precision oncology solutions. This funding will support the expansion of clinical trials and the rollout of their innovative therapies in these regions.

## Funding rounds

- Series A, May 8, 2017, $23M — Vivo Capital, Decheng Capital, Bristol-Myers Squibb Company, Hermed Capital, 3B Future Health Fund, Star Summit Ventures

## Investors

- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series A
- Bristol-Myers Squibb Company — Series A
- Hermed Capital (https://capitalatlas.ai/funds/hermed-capital) — Series A
- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Series A
- Star Summit Ventures (https://capitalatlas.ai/funds/star-summit-ventures) — Series A